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The effects of polymorphisms in genes coding for key folate metabolism enzymes such as thymidylate synthetase (TS) on colorectal
neoplasia risk are likely to be influenced by gene–gene and gene–nutrient interactions. We investigated the combined effects of
three polymorphisms in the TS gene region, TSER, TS 3R G4C, and TS 1494del6, dietary intakes of folate and other B vitamins, and
genotype for other folate metabolism variants, in a colorectal adenoma (CRA) case–control study. Individuals homozygous for TS
1494del6 del/del were at significantly reduced CRA risk compared to those with either ins/del or ins/ins genotypes (odds ratio 0.52;
95% confidence interval: 0.31–0.85, P¼0.009). We also observed evidence of interactions between TS 1494del6 genotype and
intake of folate, and vitamins B6 and B12, and MTHFR C677T genotype, with the reduction in risk in del/del homozygotes being largely
confined to individuals with high nutrient intakes and MTHFR 677CC genotype (Pinteraction¼0.01, 0.006, 0.03, and 0.07, respectively).
TSER genotype, when considered either alone or in combination with TS 3R G4C genotype, did not significantly influence CRA risk.
These findings support a role for TS in colorectal carcinogenesis, and provide further evidence that functional polymorphisms in folate
metabolism genes act as low-risk alleles for colorectal neoplasia and participate in complex gene–gene and gene–nutrient
interactions.
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Folate coenzymes, acting as donors and acceptors of one-carbon
units, play important roles in both DNA methylation and DNA
synthesis, aberrations of which are known to play a major role in
colorectal carcinogenesis (Choi and Mason, 2002). Functional
polymorphisms in the genes coding for folate metabolism enzymes
have the potential to influence either or both of these processes,
making them attractive candidates as low-risk alleles for colorectal
neoplasia (Sharp and Little, 2004). The relationship between
polymorphism genotype and colorectal neoplasia risk is likely to
be influenced by dietary factors that also alter enzyme function or
availability of one-carbon units; thus, simultaneous consideration
of both genotype and relevant dietary exposures is highly desirable
when investigating disease risk (Kim, 1999).
Thymidylate synthetase (TS) is a key enzyme in folate
metabolism catalysing the conversion of deoxyuridine monophos-
phate to deoxythymidine monophosphate, providing the sole
de novo source of thymidine required for DNA synthesis and
repair (Choi and Mason, 2000) (Figure 1). The TS substrate, 5,10-
methylenetetrahydrofolate (5,10-methyleneTHF), is also a sub-
strate for the methylenetetrahydrofolate reductase (MTHFR)
enzyme in the production of 5-methylTHF, which is in turn
converted into methionine required for DNA methylation. Thus,
the reaction catalysed by TS alters the balance of folate metabolism
away from DNA methylation and towards DNA synthesis.
Three polymorphisms mapping to the TS gene region, TSER,
TSER 3R G4C, and TS 1494del6, alter either TS expression or TS
mRNA stability (Horie et al, 1995; Ulrich et al, 2000; Pullarkat
et al, 2001; Kawakami and Watanabe, 2003; Mandola et al, 2003,
2004), and have been reported in some studies to influence
colorectal neoplasia risk when investigated individually (Ulrich
et al, 2002, 2005; Chen et al, 2003). To date, no study has reported
on the combined influence of all three polymorphisms, and we
sought to address this by genotyping individuals in a large
colorectal adenoma (CRA) case–control study including 673 cases
and 301 controls. Other folate metabolism polymorphisms, in
particular MTHFR C677T, may impact on the relationship between
TS genotype and CRA risk (Ulrich et al, 2002); therefore, study
participants were also genotyped for this and other putatively
functional folate metabolism variants. Detailed data on folate and
other B-vitamin intakes were also collected, permitting examina-
tion of potential gene–nutrient interactions.
Our principle prior hypothesis, based in part on results from
studies of colorectal cancer (CRC) risk, was that TS genotypes
associated with reduced enzyme function would be associated
with reduced CRA risk. Due to their shared substrate, 5,10-
methyleneTHF, we also anticipated gene–gene interactions
between the TS and MTHFR variants. Gene–nutrient interactions
were anticipated since B vitamins are cofactors for folate
metabolism enzymes.
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sMATERIALS AND METHODS
Study population
Cases were recruited from two sources between 2001 and 2005.
Five hundred and sixty-six cases were recruited from the UKCAP
(United Kingdom Colorectal Adenoma Prevention) trial, a recently
completed multicentre randomised trial of aspirin and folate for
the prevention of CRA recurrence (Logan et al, 2006). A further
107 cases were recruited from colonoscopy clinics in the Midlands
region of the United Kingdom. Regular aspirin or nonsteroidal
anti-inflammatory drug (NSAID) use was an exclusion criteria for
entry into the UKCAP trial. Patients excluded from UKCAP
because of regular aspirin or NSAID use were not included in our
study. The 107 additional CRA cases in our study were ascertained
after recruitment to UKCAP was completed, and were therefore
not considered for entry into the UKCAP study, thus, aspirin or
NSAID use was not an exclusion criteria for these participants. All
673 cases had one or more histologically confirmed CRAX0.5cm
in size removed at full colonoscopy in the 6 months prior to
enrolment. Individuals found to be free of adenoma on full
colonoscopy at clinics in the Midlands region, and without a
previous history of CRA or CRC, were recruited as controls. Three
hundred and one controls were recruited between 2003 and 2005.
Indications for colonoscopy included rectal bleeding or anaemia,
altered bowel habit, abdominal symptoms, a family history of CRC,
and asymptomatic screening (Table 1). All cases and controls were
of Caucasian ethnicity.
Informed consent for the study was obtained from all
participants, and the study was carried out with the Ethical
Review Board approval in accordance with the tenets of the
Declaration of Helsinki.
Questionnaire data
Face-to-face interviews were conducted in the subjects’ own home
by dedicated research staff to gather information on lifestyle and
medical factors, including ethnicity, demographic information,
past medical history, detailed family history data, aspirin and
NSAID use, multivitamin and individual vitamin supplement use,
alcohol intake, smoking, and anthropometric measurements. For
alcohol intake and smoking, subjects were asked about their
average weekly consumption of beers, wine, and spirits, separately,
or number of cigarettes smoked per day, in 10-year time intervals
from the age of 10 years. From this information, the mean number
of units of alcohol consumed per week in the 10-year time period
prior to recruitment, and total number of pack years of cigarette
smoking were calculated. All subjects also completed a food-
frequency questionnaire (FFQ), which addressed their dietary
intake in the 5 years prior to recruitment. To remove patients
whose diet was inadequately captured by the FFQ, and incorrectly
completed FFQs, patients with the highest and lowest 2.5% of
energy intakes, or questionnaires with more than 10 empty data
lines were excluded, leaving 583 cases and 277 controls in the
dietary analyses. Nutrient intakes were determined using a
nutrient conversion database, and adjusted for total energy intake
using the linear residual regression method of Willett and
Stampfer (Willett and Stampfer, 1986). Nutrient intake from
supplements was not energy adjusted.
For cases recruited from the UKCAP study, both lifestyle and
FFQs were completed at the time of entry to the UKCAP study,
while for the remaining cases and all controls, questionnaires were
completed at the time of recruitment to this study.
Polymorphism selection
Candidate folate metabolism polymorphisms, other than the TSER,
TSER 3R G4C, and TS 1494del6 variants were selected for
genotyping on the basis of a priori evidence for functional effects
on expressed proteins, and an influence on colorectal neoplasia
risk. Database and literature searches were performed to establish
a hierarchy of polymorphisms most likely to influence CRA risk,
either directly or through interactions with folate metabolism-
related dietary factors. The polymorphisms analysed were MTHFR
C677T, MTHFR A1298C, MTR A2756G, and MTRR A66G.
Genotyping
Constitutional DNA was extracted from EDTA venous blood
samples using a standard salt extraction procedure, and quantified
by PicoGreen (Invitrogen, Paisley, UK). The TSER and TS 1494del6
polymorphisms were analysed using fluorescent size discrimina-
tion on an ABI 3100 genetic analyser (Applied Biosystems, Foster
City, CA, USA). A previously described PCR–RFLP assay was used
to generate the TSER 3R G4C polymorphism genotypes (Mandola
et al, 2003). Briefly, amplified fragments were digested with HaeIII
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Figure 1 Schematic representation of folate metabolism. Corresponding enzymes for genes with polymorphisms investigated in this study are boxed. B
vitamin cofactors are in ovals. TS, thymidylate synthase; MTHFR, methylenetetrahydrofolate reductase; MTR, methionine synthase; MTRR methionine
synthase reductase; THF, tetrahydrofolate; DHF, dihydrofolate; dUMP, deoxyuridine monophosphate; dTMP, deoxythymidine monophoshate; SAM,
S-adenosylmethionine; SAH, S-adenosylhomocysteine.
TS polymorphisms, folate and B-vitamins, and CRA risk
RA Hubner et al
1450
British Journal of Cancer (2007) 97(10), 1449–1456 & 2007 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
srestriction enzyme (New England Biolabs, Hitchin, UK), and the
digestion products separated by electrophoresis on a 4% agarose
gel. HaeIII digestion of the 3RG fragment produced bands of 11-,
27-, 28-, 44-, 47-, and 66-bp, while digestion of the 3RC fragment
produced bands of 11-, 27-, 44-, 47-, and 94-bp. TSER genotypes
were then divided into high (3RG/3RG, 3RG/3RC, and 3RG/2R)
and low (3RC/3RC, 3RC/2R, and 2R/2R) TS expression groups
(Mandola et al, 2003). MTHFR C677T, MTHFR A1298C, MTR
A2756G, and MTRR A66G genotypes were generated using
Taqman technology implemented on an ABI 7900HT sequence
detection system (Applied Biosystems).
Genotyper (version 3.7) and ABI Prism 7900HT Sequence
Detection System (version 2.1) software (Applied Biosystems) were
used for fluorescent size discrimination and Taqman genotyping
analyses, respectively. Genotyping assays for each polymorphism
were validated using control samples of known homozygote wild-
type, heterozygote, and homozygote variant genotype generated by
direct sequencing. Unblinded control samples were included on
each sample plate, and were correctly genotyped on 100% of
occasions. Positive call rates for Taqman and Genescan analyses
were 99 and 98%, respectively. Details of all PCR primer sequences
and reaction conditions are available on request.
Statistical analysis
The w
2 and t-tests were used to compare baseline characteristics
between cases and controls, and to test genotype frequencies in the
control group for evidence of departure from Hardy–Weinberg
equilibrium. The relationship between genotype and risk of CRA
was assessed by means of odds ratios (ORs) and 95% confidence
intervals (CIs) calculated using unconditional logistic regression.
Both unadjusted and adjusted ORs were calculated. Variables for
sex, smoking, alcohol intake, and dietary intakes of fibre, folate,
and vitamins B2 and B6 (from food and supplements combined)
were included in adjusted analyses as these variables were found
to significantly influence CRA risk. Aspirin or NSAID use was not
included in multivariate analyses as it was an exclusion criterion
for recruitment into the aspirin intervention trial from which the
majority of cases were drawn. All adjustment variables were
included in the model as continuous variables, apart from sex
and alcohol intake, which was included as sex-specific tertiles.
The associations between genotype and CRA risk were initially
evaluated in the entire population, and subsequently separately in
men and women. Further subsets of the population were based on
polyp characteristics.
We then considered genotypes in combination with intakes of
alcohol, and dietary folate and vitamins B2,B 6, and B12. Energy-
adjusted tertile cut points were used to designate low (lowest
tertile), medium (middle tertile), and high (highest tertile) dietary
intakes based on the distribution in control subjects. Alcohol
intake tertiles were calculated for men and women separately, and
tertiles for micronutrients were calculated for food-only intake,
and for intake from food and supplements combined. Effect
modification was evaluated by stratification on the variable of
interest, and ORs within each stratum were compared. To test for
linear trend, the tertile of nutrient intake was included as a
continuous variable in the logistic regression model in which each
tertile was assigned its median value. Interactions between
variables with respect to CRA risk were explored using likelihood
ratio testing comparing models with and without a multiplicative
term for the two variables.
We also performed haplotype analysis for the TSER and TS
1494del6 variants and the MTHFR C677T and A1298C variants
using genotype data from all subjects to infer chromosomal phase.
Haplotypes were analysed using PHASE software, which imple-
ments the expectation-maximisation algorithm to estimate haplo-
type frequencies and individual haplotypes (Stephens et al, 2001).
Possible haplotypes were tested for association with CRA risk by
taking the most likely pair of haplotypes for each subject.
Statistical analyses were undertaken using STATA, version 8.2
(Stata Corporation, College Station, TX, USA), with the exception
of the haplotype analyses above. All tests were two sided, and a
P-value less than 0.05 was considered significant.
RESULTS
Characteristics of the study population are shown in Table 1. Cases
were more likely to be men and smokers than controls, and had a
Table 1 Characteristics of the study population
Variable Cases (n¼673) Controls (n¼301) P
a
Indication for colonscopy
Asymptomatic/screening 6% 15%
Bleeding/anaemia 55% 45%
Altered bowel habit 5% 15%
Abdominal symptoms 10% 14%
Other 8% 19%
Unknown 16% 6%
Location of largest adenoma
Proximal colon 9%
Distal colon 64%
Rectum 23%
Unknown 3%
Multiple polyps
b 17%
Advanced adenoma
c 61%
Sex
Female 46.5% 60.5% o0.01
Male 53.5% 39.5%
Age
d 57.8 (9.9) 58.6 (12.7) 0.29
Family history
e 25% 26% 0.80
BMI
d 26.3 (4.1) 26.3 (4.7) 0.86
Smoking
Pack years
d 15.6 (18.7) 12.3 (16.8) o0.01
Never 37% 45%
Ever 63% 55% 0.02
Regular aspirin/NSAID use
f 28% 35% 0.22
Alcohol
Men
Mean (s. d.)
g 19.2 (19.8) 15.9 (21.8) 0.13
None 13% 19%
Women
Mean (std dev)
g 7.4 (11.9) 5.1 (6.8) 0.02
None 32% 38%
Dietary fibre intake (g)
d,h 20.5 (6.1) 22.4 (6.9) o0.01
Nutrient intake (excluding supplements)
d,h
Folate (mgday
 1) 304 (96) 340 (109) o0.01
Vitamin B2 (mgday
 1) 2.47 (0.54) 2.54 (0.56) 0.10
Vitamin B6 (mgday
 1) 2.25 (0.56) 2.46 (0.67) o0.01
Vitamin B12 (mgday
 1) 6.80 (3.04) 6.92 (3.01) 0.58
Nutrient intake (including supplements)
d,h
Folate (mgday
 1) 336 (129) 387 (152) o0.01
Vitamin B2 (mgday
 1) 2.70 (0.83) 2.87 (0.96) 0.01
Vitamin B6 (mgday
 1) 2.54 (0.94) 2.88 (1.20) o0.01
Vitamin B12 (mgday
 1) 6.95 (3.07) 7.13 (3.05) 0.41
BMI, body mass index.
aP-value based on w
2 and t-tests.
bX3 polyps.
cVillous or
tubulovillous features, size X1cm, or severe dysplasia.
dMean (s.d.).
eFamily history of
colorectal cancer in one or more first-degree relative.
fAt least one tablet per month
for at least a year, data for cases includes only those recruited outside the UKCAP
trial (n¼107), since aspirin or NSAID use was an exclusion criterion for this trial.
gUnits per week.
hEnergy-adjusted dietary nutrient intakes.
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shigher intake of alcohol. There were no significant differences
between cases and controls in terms of age, family history of CRC,
and body mass index. Energy adjusted dietary fibre intake was
higher in controls, as were intakes of folate, and vitamins B2 and
B6 when either intake from food only or intake from food and
supplements combined was considered.
Allele frequencies for all polymorphisms were similar to
previous reports in Caucasian populations, and all genotype
frequencies in control subjects were in Hardy–Weinberg equili-
brium (Le Marchand et al, 2002; Ulrich et al, 2002; Ogino and
Wilson, 2003; Goode et al, 2004). We observed TSER repeat
polymorphism alleles with four and six repeats (allele frequencies
0.2 and 0.1%, respectively) as has previously been reported (Marsh
et al, 2000), and since the functional significance of such alleles is
uncertain, subjects carrying these alleles were excluded from TSER
association analyses. We also observed a TSER two-repeat allele
with a C base at position 12 of the first repeat with a frequency of
0.5%, confirming a recent report of the existence of a TSER 2RC
allele (Gusella et al, 2006).
Both TS 1494del6 and MTHFR C677T genotypes influenced CRA
risk (Table 2). Individuals homozygous for the TS 1494del6
deletion were at 50% reduced risk compared to homozygous
wild-type or heterozygous individuals combined (OR 0.52; 95%
CI: 0.31–0.85, P¼0.009), and the inverse association was more
apparent when the analysis was restricted to cases whose largest
adenoma was located in the colon rather than the rectum (OR 0.40;
95% CI: 0.23–0.71 and OR 0.87; 95% CI: 0.45–1.68, respectively).
Individuals with homozygous MTHFR 677TT genotype were at
significantly increased CRA risk compared to wild-type individuals
and heterozygotes combined (OR 1.71; 95% CI: 1.03–2.86,
P¼0.04), and this influence was more apparent in men than
women (OR 2.27; 95% CI: 0.90–5.73 and OR 1.41; 95% CI: 0.74–
2.66, respectively), and when the analyses were restricted to cases
whose largest adenoma was located in the rectum (OR 2.40; 95%
CI: 1.24–4.62). Adjustment for MTHFR C677T polymorphism
genotype did not significantly alter the association between TS
1494del6 and adenoma risk; however, when stratified by both TS
1494del6 and MTHFR C677T genotypes, the reduced risk
associated with the del/del genotype was confined to individuals
with CC genotype (OR 0.31; 95% CI; 0.15–0.63 for CC genotype
individuals, and OR 1.02; 95% CI: 0.43–2.40 for CT/TT genotypes,
Pinteraction¼0.07). When the two variants were considered in
combination, an over threefold increased risk (OR 3.68; 95% CI:
1.67–8.10, P¼0.001) was observed in individuals with ‘high-risk’
genotypes for both variants (ins/ins or ins/del for the TS 1494del6
variant and MTHFR TT homozygotes) compared to individuals
with ‘low-risk’ genotypes (del/del and CC or CT). When the TS
1494ins and MTHFR 677T alleles were considered ‘high-risk
alleles’, and the number of high-risk alleles carried was included
as a continuous variable in the analysis, then each additional
high-risk allele was associated with a 20% (95% CI: 3–40%,
Ptrend¼0.02) incremental increase in risk.
We also observed significant interactions between TS 1494del6
genotype and dietary food intakes of folate, and vitamins B6 and
B12 (Table 3). Among individuals with folate intake X383mgday
 1
(highest tertile), those with del/del genotype were at markedly
reduced CRA risk compared to those with ins/ins genotype,
whereas in individuals with folate intake below 383mgday
 1 (low/
medium tertile), the del/del genotype was associated with only a
modest risk reduction. Similar interactions between TS 1494del6
genotype and vitamin B6 and B12 intakes were observed with the
risk reduction associated with the del/del genotype consistently
being confined to individuals with high nutrient intakes. Adjusting
for MTHFR C677T genotype did not modify these gene–nutrient
interactions, and similar interactions were observed if nutrient
intake from food and supplements combined was considered
(Pinteraction¼0.07, 0.006, and 0.02, for folate, and vitamin B6 and
B12 intakes, respectively). Furthermore, these gene–nutrient
interactions were robust to other methods of classifying nutrient
intake such as above and below median intake, with the lowest
risks consistently occurring in individuals with high-nutrient
intakes and del/del genotype. The Pint-values for the interactions
between TS 1494del6 genotype and nutrient intakes of folate, and
vitamins B6 and B12 from food only categorised into two groups
(high and low based on the median values in control subjects,
folate 340mgday
 1, vitamin B6 2.42mgday
 1, and vitamin B12
6.32mgday
 1) were 0.18, 0.04, and 0.12, respectively. The
corresponding values for nutrient intakes from food and
supplements combined were 0.08, 0.01, and 0.09, respectively
(corresponding median values 372mgday
 1, 2.58mgday
 1, and
6.59mgday
 1).
We also observed evidence of interactions between folate and
alcohol intake and MTHFR C677T genotype, although nonsigni-
ficantly, with the highest adenoma risks occurring in individuals
with the MTHFR 677TT genotype and low/medium folate or high/
medium alcohol intakes. Although when subjects were classified
into high- and low-folate groups based on the median intake, the
MTHFR 677TT genotype conferred an increased risk regardless of
folate intake. There were no significant interactions between
MTHFR C677T genotype and vitamin B2,B 6, and B12 intakes.
TSER polymorphism genotype did not significantly alter CRA
risk, and further stratification into putative high and low TS
expression groups on the basis of TSER 3R G4C polymorphism
genotype did not result in a significant association (Table 2). When
Table 2 Association of genotype and colorectal adenoma risk
Variant Genotype
No. of case/
control
Unadjusted OR
(95% CI)
Adjusted OR
(95% CI)
a
TSER 3R/3R 191/101 Ref Ref
3R/2R 330/133 1.31 (0.96–1.80) 1.21 (0.86–1.69)
2R/2R 147/66 1.18 (0.81–1.72) 1.19 (0.79–1.80)
TSER High/
low
b
High 257/126 Ref Ref
Low 411/174 1.16 (0.88–1.53) 1.16 (0.86–1.56)
TS
1494del6
Ins/ins 337/143 Ref Ref
Ins/del 288/119 1.03 (0.77–1.37) 0.97 (0.71–1.33)
Del/del 48/39 0.52 (0.33–0.83)
w 0.51 (0.30–0.85)
w
MTHFR
C677T
CC 306/143 Ref Ref
CT 289/133 1.02 (0.76–1.35) 0.99 (0.73–1.35)
TT 78/25 1.46 (0.89–2.39) 1.71 (1.00–2.92)
z
MTHFR
A1298C
AA 331/135 Ref Ref
AC 277/128 0.88 (0.66–1.18) 0.85 (0.62–1.16)
CC 65/38 0.70 (0.45–1.09) 0.65 (0.41–1.05)
MTR
A2756G
AA 461/191 Ref Ref
AG 191/98 0.81 (0.60–1.09) 0.80 (0.57–1.09)
GG 21/12 0.73 (0.35–1.50) 0.99 (0.45–2.15)
MTRR
A66G
AA 140/58 Ref Ref
AG 322/137 0.97 (0.68–1.40) 0.98 (0.66–1.45)
GG 211/106 0.82 (0.56–1.21) 0.86 (0.57–1.30)
OR¼Odds ratio; 95% CI¼95% confidence interval.
aAdjusted for sex, smoking,
alcohol consumption, and dietary fibre, folate, and vitamins B2 and B6 (from food and
supplements).
bHigh-expression TSER genotypes are 3RG/3RG, 3RG/3RC, and
3RG/2RG, and low expression genotypes are 3RC/3RC, 3RC/2RG, and 2RG/2RG.
wP¼0.01
zP¼0.05.
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food and supplements combined, no consistent patterns were
observed. A trend towards a reduced CRA risk was observed in
MTHFR 1298CC homozygotes, while MTR A2756G and MTRR
A66G genotypes did not influence risk (Table 2), and there were no
significant gene–nutrient interactions.
Linkage disequilibrium was observed between both the TSER
and TS 1494del6, and the MTHFR C677T and A1298C polymor-
phisms with r
2 values of 0.11 and 0.22, respectively. Four TS
haplotypes and three MTHFR haplotypes were observed (Table 4).
Prior functional data suggest that the TS 3R/ins and MTHFR 677A/
1298C haplotypes will confer the highest TS protein expression/
mRNA stability and MTHFR enzyme function, respectively (Frosst
et al, 1995; Weisberg et al, 1998; Kawakami and Watanabe, 2003;
Mandola et al, 2003, 2004). Using these haplotypes as the reference
groups in haplotype analyses, no significant associations between
either MTHFR or TS haplotypes and CRA risk were observed.
DISCUSSION
Our finding of a reduced CRA risk in individuals homozygous for
the TS 1494del6 variant adds to the increasing evidence supporting
a role for altered TS expression in colorectal carcinogenesis.
Presence of the deleted allele has been reported to result in
enhanced TS mRNA degradation in vitro, and two clinical studies
have observed reduced TS mRNA expression in colorectal tumours
of del/del homozygote patients (Lenz et al, 2002; Mandola et al,
2004). In a recent study of CRC patients receiving 5-fluorouracil
(5-FU)-based adjuvant chemotherapy, patients heterozygous or
homozygous for the deleted allele had an improved survival
indicating likely increased sensitivity to TS inhibition, providing
further evidence that this polymorphism is functional (Dotor et al,
2006). Furthermore, the largest previous case–control study
investigating the association of TS 1494del6 genotype and colo-
rectal neoplasia risk, reported a reduced CRC risk in women
homozygous for the deleted allele (Ulrich et al, 2005).
Table 3 Association of TS 1494del6 and MTHFR C677T genotypes and colorectal adenoma risk stratified by nutrient intake
Genotype
TS1494del6
Tertiles of nutrient intake from food only
a Ins/ins Ins/del Del/del Pinteraction
Folate
High
No. of cases/controls 63/54 49/23 5/14
OR (95% CI)
b Ref 1.82 (0.96–3.49) 0.30 (0.10–0.95)
Low/medium
No. of cases/controls 240/81 189/85 37/20
OR (95% CI)
b 1.53 (0.89–2.64) 1.13 (0.65–1.95) 1.19 (0.51–2.75) 0.01
Vitamin B2
High
No. of cases/controls 84/49 52/33 7/10
OR (95% CI)
b Ref 1.00 (0.56–1.80) 0.35 (0.12–1.01)
Low/medium
No. of cases/controls 219/86 186/75 35/24
OR (95% CI)
b 1.05 (0.66–1.69) 1.07 (0.66–1.73) 0.55 (0.26–1.17) 0.86
Vitamin B6
High
No. of cases/controls 59/53 57/25 8/13
OR (95% CI)
b Ref 2.26 (1.21–4.23) 0.52 (0.20–1.41)
Low/medium
No. of cases/controls 244/82 181/83 34/21
OR (95% CI)
b 1.54 (0.90–2.65) 1.09 (0.61–1.94) 1.46 (0.46–4.59) 0.006
Vitamin B12
High
No. of cases/controls 87/43 61/29 9/19
OR (95% CI)
b Ref 1.23 (0.67–2.29) 0.25 (0.10–0.63)
Low/medium
No. of cases/controls 216/92 177/79 33/15
OR (95% CI)
b 1.39 (0.86–2.24) 1.00 (0.62–1.62) 1.00 (0.45–2.22) 0.03
Alcohol
Low
No. of cases/controls 94/40 77/47 8/13
OR (95% CI)
b Ref 0.61 (0.35–1.05) 0.23 (0.08–0.71)
High/medium
No. of cases/controls 243/103 211/72 40/26
OR (95%CI)
b 0.89 (0.55–1.42) 1.04 (0.63–1.73) 0.57 (0.28–1.14) 0.11
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combined TSER and TSER 3R G4C polymorphism genotypes and
colorectal neoplasia risk. Functional data from in vitro experi-
ments suggest that 3RG alleles confer increased TS mRNA
expression compared to either 3RC or 2R alleles, and consideration
of the G4C polymorphism may allow more accurate stratification
of individuals into high and low TS expression groups (Kawakami
and Watanabe, 2003; Mandola et al, 2003). On this basis, our
findings of nonsignificantly increased CRA risks in low-expression
genotype groups, when categorised either by TSER genotype alone
or in combination with the 3R G/C polymorphism, is seemingly at
odds with the reduced CRA risk in individuals homozygous for the
TS 1494del6 variant. More recent data, however, indicate that
functional predictions based on in vitro tests may not reflect the
real situation in vivo (Etienne et al, 2002; Jakobsen et al, 2005;
Dotor et al, 2006). For example, while studies have reported
increased TS mRNA expression in human colorectal tumours from
individuals with 3R/3R genotype, the only study of TS protein
activity reported an increased activity in tumours harbouring the
3R/2R genotype, indicating the existence of additional post-
transcriptional regulatory pathways (Etienne et al, 2002). Addi-
tionally, two recent studies of 5-FU chemotherapy in patients with
CRC, one in the adjuvant setting and one in patients with
metastatic disease, both reported significantly improved outcomes
in individuals with 3R/3R genotype (Jakobsen et al, 2005; Dotor
et al, 2006). Thus prediction of TS protein activity in either normal
or tumour tissue based on TS polymorphism genotypes is far from
straightforward, and discrepancies in associations between color-
ectal neoplasia risk and TS genotypes with apparently similar
functional effects are not uncommon (Ulrich et al, 2002, 2005;
Adleff et al, 2004). Three previous studies, two in US populations
and one in a Dutch population, have investigated the relationship
between TSER genotype and CRA risk (without consideration of
the TSER 3R G/C polymorphism), and in concordance with our
study, all three reported no significant association (Ulrich et al,
2002; Chen et al, 2004; van den Donk et al, 2007). One of these
studies also genotyped the TS 1494del6 variant and in contrast to
our study found no significant influence on CRA risk (Ulrich et al,
2002). This discrepancy may reflect a genuine difference in the
gene–disease association between different populations, effect
modification due to different population intakes of micronutrients,
or may simply be due to chance.
Our finding of significant interactions between folate, and
vitamin B6 and B12 intakes and TS 1494del6 genotype provide
further evidence that assessment of genotype alone will be
insufficient to determine an individuals’ risk of colorectal
neoplasia. Similar gene–nutrient interactions have been reported
with other polymorphisms in folate metabolism genes, in
particular the MTHFR C677T variant (Ma et al, 1997), and it is
entirely plausible that the risks conferred by low penetrance
colorectal susceptibility alleles may be influenced by environ-
mental exposures that impact on the same metabolic pathways.
The reduced CRA risk associated with the homozygous del/del
genotype seen in our study is most likely due to an increased
availability of 5,10-methyleneTHF for use in DNA methylation.
Enhancement of this protective effect by dietary factors that also
result in increased 5,10-methyleneTHF, such as vitamin B6 and
folate, and others that allow increased cycling of methyl groups
towards methylation, such as vitamin B12, provides further
evidence for this model. As does the observation that the
protective effect of the del/del genotype was confined to carriers
of the MTHFR 677CC genotype that allows efficient metabolism of
5,10-methyleneTHF.
Folate
High
No. of cases/controls 51/37 47/46 19/8
OR (95% CI)
b Ref 0.71 (0.38–1.34) 1.79 (0.67–4.78)
Low/medium
No. of cases/controls 214/93 201/79 51/14 0.59
OR (95% CI)
b 1.44 (0.81–2.57) 1.37 (0.76–2.48) 2.28 (0.94–5.57)
Alcohol
Low
No. of cases/controls 81/53 79/40 19/7
OR (95% CI)
b Ref 1.29 (0.74–2.24) 1.67 (0.63–4.46)
High/medium
No. of cases/controls 225/90 210/93 59/18
OR (95% CI)
b 1.47 (0.92–2.33) 1.30 (0.80–2.09) 2.41 (1.21–4.83) 0.44
aCut points for tertiles of dietary intakes: folate (mgday
 1) 295/383; vitamin B2 (mgday
 1) 2.29/2.84; vitamin B6 (mgday
 1) 2.18/2.71; vitamin B12 (mgday
 1) 5.30/7.65, alcohol
(units per week) men 3/15, women 1/8.
bOdds ratios and 95% confidence intervals adjusted for sex, smoking, alcohol consumption, and dietary intakes of fibre, folate, and
vitamins B2 and B6 (from food and supplements) where appropriate.
Table 4 Association of TS and MTHFR haplotypes and colorectal
adenoma risk
Gene Haplotype
Frequency
(%)
No. of
case/control
OR
(95% CI)
a
TS 3R/ins 28.6 384/169 Ref
2R/ins 41.7 572/236 1.02 (0.79–1.31)
3R/del 25.5 328/166 0.80 (0.61–1.07)
2R/del 4.2 52/29 0.84 (0.49–1.45)
MTHFR 677C/1298A 36.4 494/215 Ref
677T/1298A 32.2 445/183 0.92 (0.66–1.29)
677C/1298C 31.4 407/204 0.85 (0.66–1.09)
aOdds ratios and 95% confidence intervals adjusted for sex, smoking, alcohol
consumption, and dietary intakes of fibre, folate, and vitamins B2 and B6 (from food
and supplements).
Table 3 (Continued)
Genotype
MTHFR C677T
Tertiles of nutrient intake from food only
a CC CT TT Pinteraction
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their colonoscopy were known, which might have led to
ascertainment bias, and all subjects completed FFQs once their
disease status was known, which might have led to recall bias. The
use of controls known to be adenoma free, however, has the
advantage of avoiding the loss of power associated with incorrect
classification of cases and controls, and the indications for
colonoscopy were not related to genotype for any of the variants
studied. Other strengths of this study include its relatively large
sample size, and the collection of data on multiple genetic and
dietary factors, allowing investigation of, and where appropriate,
adjustment for, gene–gene and gene–nutrient interactions. All
control subjects in this study were recruited from the Midlands
region, whereas 35% of cases were from non-Midlands UK areas.
This difference in geographical location occurred because a
proportion of case subjects recruited through UKCAP were from
northern and western UK regions. Although this discrepancy has
the potential to bias associations between dietary factors and CRA
risk due to regional differences in diet, it will not confound
genotype associations since geographical location is unlikely to be
a determinant of genotype among UK Caucasians (The Wellcome
Trust Case Control Consortium, 2007). In analyses restricted to
cases from the Midlands region, individuals homozygous for the
TS 1494del6 variant remained at reduced CRA risk (OR 0.50; 95%
CI: 0.28–0.89), and the interactions between TS 1494del6 genotype
and dietary intakes of folate, and vitamins B6 and B12 remained
significant (P¼0.02, 0.01, and 0.02, respectively). The majority of
cases in our study were recruited from the UKCAP trial in which
aspirin or NSAID use was an exclusion criterion, whereas this
exclusion criterion was not applied to controls recruited to our
study, making aspirin use a potential confounder. Current
literature, however, provide little evidence of a relationship
between aspirin or NSAID use and genotype for the variants we
tested, or for interactions between genotype and aspirin or NSAID
use in determining risk of CRA or CRC, hence, we feel our
observations are unlikely to have been influenced by such
confounding.
In summary, we observed an influence of TS 1494del6 genotype
on CRA risk, which was largely confined to subgroups of the
population defined by dietary intakes of folate and other B
vitamins, and MTHFR C677T genotype. Our study adds to the
growing body of evidence indicating that functional polymor-
phisms in folate metabolism genes act as low penetrance
susceptibility alleles for colorectal neoplasia, and participate in
complex gene–gene and gene–nutrient interactions.
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